IAG to present 5 abstracts at EULAR

IAG’s Scientific Team to present five abstracts at the Annual European Congress of Rheumatology 2019

Dr. Olga Kubassova, CEO of IAG will be attending the Annual European Congress of Rheumatology, EULAR, 12-15 June 2019, Madrid, Spain together with IAG’s scientific advisory board team members: Prof. Ali Mobasheri, the President-Elect, Osteoarthritis Research Society International (OARSI) and Prof. Mikael Boesen, the Head of IAG’s Musculoskeletal Imaging Research.

Five abstracts by IAG’s team and scientific and industry collaborators were accepted in this industry’s leading rheumatology scientific meeting. These discuss new trial designs and novel approaches to understanding #lupus, inflammatory #arthritis (PsA and RA), #inflammation, #pain and #damage.

These works are based on the results of innovative clinical research studies, which involve state-of-the-art and cutting-edge advanced imaging techniques, our quantitative methodologies for assessment of treatment efficacy, including some that are based on Machine Learning and AI principals.

We warmly thank our collaborators, scientific advisors and biotechnology and pharmaceutical partners for their contributions and delighted to share the details of the abstracts below.

If you are interested to discuss during EULAR, email: contact@ia-grp.com

ABSTRACTS:

EFFECT OF LIRAGLUTIDE ON BODY WEIGHT AND PAIN IN THE TREATMENT OF OVERWEIGHT AND KNEE OSTEOARTHRITIS: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, Eva Ejlersen Wæhrens, Henning Bliddal, Robin Christensen, Sabrina Mai Nielsen, Mikael Boesen, Filip Krag Knop, Arne Astrup, Marianne Uggen Rasmussen, Cecilie Rødgaard Bartholdy, Cecilie Daugaard, Else Marie Bartels, Karen Ellegaard, Berit Lilienthal Heitmann, Lars Erik Kristensen

In this study we demonstrate the effect of Liraglutide (GLP-1 receptor agonist) treatment on the diet-induced weight loss and knee pain in patients with concomitant knee osteoarthritis (OA) and overweight.

Details of the methods will be discussed during oral presentation at EULAR, Session: Pharmaceutical pipeline in OA, on 12th June 2019 14:15 – 15:45, location: N101/N102.

MAGNETIC RESONANCE IMAGING TENOSYNOVITIS AND OSTEITIS ARE INDEPENDENT PREDICTORS OF RADIOGRAPHIC AND MRI DAMAGE PROGRESSION IN RHEUMATOID ARTHRITIS PATIENTS IN CLINICAL REMISSION, Signe Møller-Bisgaard, Kim Hørslev-Petersen, Bo Ejbjerg, Merete L. Hetland, Lykke Ørnbjerg, Daniel Glinatsi, Jakob Møllenbach Møller, Mikael Boesen, Kristian Stengaard-Pedersen, Ole Madsen, Bente Jensen, Jan Villadsen, Ellen Margrethe Hauge, Philip Bennett, Oliver Hendricks, Karsten Asmussen, Marcin Kowalski, Hanne Merete Lindegaard, Henning Bliddal, Niels Steen Krogh, Torkell Ellingsen, Agnete Nielsen, Lone Balding, Anne Grethe Jurik, Henrik Thomsen, Mikkel Ǿstergaard

This study demonstrates that novel MRI-based biomarkers for inflammation and damage during tenosynovitis independently predict both X-ray and MRI damage progression in rheumatoid arthritis (RA) patients in clinical remission.

Details of the methods and discussion on predictive value of the imaging biomarkers for monitoring pathology of RA will be discussed during oral presentation at EULAR, Session: Remission – the holy grail? Looking across diseases, on 14th June 2019, 04:45 PM – 04:55 PM, location: N117/N118

LESS SEVERE SYNOVITIS IN PATIENTS WITH KNEE OSTEOARTHRITIS IS ASSOCIATED WITH HIGHER SELF-REPORTED PAIN INTENSITY 12 MONTHS AFTER TOTAL KNEE ARTHROPLASTY – AN EXPLORATORY COHORT STUDY, Kristian Kjær Petersen, Lars Arent-Nielsen, Mikael Boesen, Jonathan Vela, Soeren Skou, Mikkel Eld, Nasir Musa Al-Mashkur, Robert Riis, Ole Simonsen

This study discusses the role of imaging biomarkers based on IAG’s proprietary DCE-MRI inflammation indices (DEMRIQ-inflammation) in evaluation of the role of pre- and perioperative synovitis in the self-reported pain 12 months after total knee arthroplasty (TKA).

Details of the methods and the clinical significance of the results will be presented EULAR, Abstract Session: Diagnostics and imaging procedures, on 13 June 2019 10:15 – 11:45, location: N103/N104.

A PHASE IV, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE IMPACT OF APREMILAST ON HAND AND WHOLE-BODY MRI OUTCOMES IN PATIENTS WITH PSORIATIC ARTHRITIS (MOSAIC): RATIONALE, DESIGN, AND METHODS, Mikkel Ǿstergaard, Walter P. Maksymowych, Mikael Boesen, Olga Kubassova, Priscila Nakasato, Benoit Guerette, Lichen Teng, Philip J. Mease

This new trial design speaks to the added value of advanced MRI-based early efficacy biomarkers in the assessment of Apremilast-based treatment of psoriatic arthritis.

Details of the methods and discussion on measuring the treatment efficacy through the imaging biomarkers will be presented at EULAR, Abstract Session: Diagnostics and imaging procedures, on 13 June 2019 10:15 – 11:45, location: N103/N104.

DEVELOPMENT OF A MULTI-MODALITY IMAGING APPROACH TO EVALUATE LUPUS NEPHRITIS AND INITIAL RESULTS, David R. Karp, Brad H. Rovin, Mikael Boesen, Olga Kubassova, Peter Lipsky

This study presents the design of a novel imaging approach for the evaluation of the spectrum of pathologic changes in lupus nephritis. Multi-modality imaging performed in the study includes dynamic contrast enhanced MRI (DCE-MRI) applied to detect changes in vascularization and perfusion, Diffusion Weighted Imaging (DWI) applied to assess interstitial diffusion, T2*Map/BOLD applied to assess the tissue oxygenation and T1rho to evaluate fibrosis.

Details of the methods and the role of imaging biomarkers in assessment of lupus nephritis will be presented at EULAR, Session: SLE, Sjögren’s and APS – clinical aspects (other than treatment), on 13 June 2019 11:50 – 13:30, Hall B

News
Events